These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
371 related articles for article (PubMed ID: 26977749)
1. Implementation and Operational Research: A Cost-Effective, Clinically Actionable Strategy for Targeting HIV Preexposure Prophylaxis to High-Risk Men Who Have Sex With Men. Ross EL; Cinti SK; Hutton DW J Acquir Immune Defic Syndr; 2016 Jul; 72(3):e61-7. PubMed ID: 26977749 [TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Juusola JL; Brandeau ML; Owens DK; Bendavid E Ann Intern Med; 2012 Apr; 156(8):541-50. PubMed ID: 22508731 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of pre-exposure prophylaxis for the prevention of HIV in men who have sex with men in South Korea: a mathematical modelling study. Choi H; Suh J; Lee W; Kim JH; Kim JH; Seong H; Ahn JY; Jeong SJ; Ku NS; Park YS; Yeom JS; Kim C; Kwon HD; Smith DM; Lee J; Choi JY Sci Rep; 2020 Sep; 10(1):14609. PubMed ID: 32884082 [TBL] [Abstract][Full Text] [Related]
4. A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China. Li J; Peng L; Gilmour S; Gu J; Ruan Y; Zou H; Hao C; Hao Y; Lau JT BMC Infect Dis; 2018 Nov; 18(1):600. PubMed ID: 30486800 [TBL] [Abstract][Full Text] [Related]
5. Optimising HIV pre-exposure prophylaxis and testing strategies in men who have sex with men in Australia, Thailand, and China: a modelling study and cost-effectiveness analysis. Zhao R; Fairley CK; Cook AR; Phanuphak N; He S; Tieosapjaroen W; Chow EPF; Phillips TR; Jin Tan RK; Wei Y; Shen M; Zhuang G; Ong JJ; Zhang L Lancet Glob Health; 2024 Feb; 12(2):e243-e256. PubMed ID: 38245115 [TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of HIV pre-exposure prophylaxis among men-who-have-sex-with-men in England in 2016. Ong KJ; Desai S; Field N; Desai M; Nardone A; van Hoek AJ; Gill ON Euro Surveill; 2017 Oct; 22(42):. PubMed ID: 29067902 [TBL] [Abstract][Full Text] [Related]
7. Cost and cost-effectiveness analysis of pre-exposure prophylaxis among men who have sex with men in two hospitals in Thailand. Suraratdecha C; Stuart RM; Manopaiboon C; Green D; Lertpiriyasuwat C; Wilson DP; Pavaputanon P; Visavakum P; Monkongdee P; Khawcharoenporn T; Tharee P; Kittinunvorakoon C; Martin M J Int AIDS Soc; 2018 Jul; 21 Suppl 5(Suppl Suppl 5):e25129. PubMed ID: 30033559 [TBL] [Abstract][Full Text] [Related]
8. Preexposure prophylaxis for men who have sex with men in the Netherlands: impact on HIV and Neisseria gonorrhoeae transmission and cost-effectiveness. Reitsema M; Hoek AJV; van der Loeff MS; Hoornenborg E; van Sighem A; Wallinga J; van Benthem B; Xiridou M AIDS; 2020 Mar; 34(4):621-630. PubMed ID: 31895142 [TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil. Luz PM; Osher B; Grinsztejn B; Maclean RL; Losina E; Stern ME; Struchiner CJ; Parker RA; Freedberg KA; Mesquita F; Walensky RP; Veloso VG; Paltiel AD J Int AIDS Soc; 2018 Mar; 21(3):e25096. PubMed ID: 29603888 [TBL] [Abstract][Full Text] [Related]
10. Use of an HIV-risk screening tool to identify optimal candidates for PrEP scale-up among men who have sex with men in Toronto, Canada: disconnect between objective and subjective HIV risk. Wilton J; Kain T; Fowler S; Hart TA; Grennan T; Maxwell J; Tan DH J Int AIDS Soc; 2016; 19(1):20777. PubMed ID: 27265490 [TBL] [Abstract][Full Text] [Related]
11. High HIV risk and syndemic burden regardless of referral source among MSM screening for a PrEP demonstration project in Toronto, Canada. Wilton J; Noor SW; Schnubb A; Lawless J; Hart TA; Grennan T; Fowler S; Maxwell J; Tan DHS BMC Public Health; 2018 Feb; 18(1):292. PubMed ID: 29486737 [TBL] [Abstract][Full Text] [Related]
12. A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men. Drabo EF; Hay JW; Vardavas R; Wagner ZR; Sood N Clin Infect Dis; 2016 Dec; 63(11):1495-1504. PubMed ID: 27558571 [TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of a Statewide Pre-Exposure Prophylaxis Program for Gay, Bisexual, and Other Men Who Have Sex with Men. Goedel WC; Chan PA; King MRF; Prosperi MCF; Marshall BDL; Galárraga O R I Med J (2013); 2019 Nov; 102(9):36-39. PubMed ID: 31675786 [TBL] [Abstract][Full Text] [Related]
14. Modelling the Epidemiological Impact and Cost-Effectiveness of PrEP for HIV Transmission in MSM in China. Zhang L; Peng P; Wu Y; Ma X; Soe NN; Huang X; Wu H; Markowitz M; Meyers K AIDS Behav; 2019 Feb; 23(2):523-533. PubMed ID: 29971734 [TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of case-finding strategies for achieving hepatitis C elimination among men who have sex with men in the UK. Macgregor L; Ward Z; Martin NK; Nicholls J; Desai M; Hickson F; Weatherburn P; Hickman M; Vickerman P J Viral Hepat; 2021 Jun; 28(6):897-908. PubMed ID: 33759257 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of HIV pre-exposure prophylaxis in Japan. Mizushima D; Nagai Y; Mezzio D; Harada K; Piao Y; Barnieh L; El Moustaid F; Cawson M; Taniguchi T J Med Econ; 2023; 26(1):886-893. PubMed ID: 37421417 [TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis. Neilan AM; Landovitz RJ; Le MH; Grinsztejn B; Freedberg KA; McCauley M; Wattananimitgul N; Cohen MS; Ciaranello AL; Clement ME; Reddy KP; Hyle EP; Paltiel AD; Walensky RP Ann Intern Med; 2022 Apr; 175(4):479-489. PubMed ID: 35099992 [TBL] [Abstract][Full Text] [Related]
18. Cost utility analysis of HIV pre exposure prophylaxis among men who have sex with men in Israel. Ginsberg GM; Chemtob D BMC Public Health; 2020 Feb; 20(1):271. PubMed ID: 32103750 [TBL] [Abstract][Full Text] [Related]
19. Competing biomedical HIV prevention strategies: potential cost-effectiveness of HIV vaccines and PrEP in Seattle, WA. Adamson B; Garrison L; Barnabas RV; Carlson JJ; Kublin J; Dimitrov D J Int AIDS Soc; 2019 Aug; 22(8):e25373. PubMed ID: 31402591 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058. van de Vijver DAMC; Richter AK; Boucher CAB; Gunsenheimer-Bartmeyer B; Kollan C; Nichols BE; Spinner CD; Wasem J; Schewe K; Neumann A Euro Surveill; 2019 Feb; 24(7):. PubMed ID: 30782266 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]